Hewer, S;
Varley, S;
Boxer, AL;
Paul, E;
Williams, DR;
AL-108-231 Investigators;
(2016)
Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.
Movement Disorders
, 31
(10)
pp. 1574-1577.
10.1002/mds.26694.
![]() |
Text
nihms839703.pdf - Accepted Version Access restricted to UCL open access staff Download (51kB) |
Abstract
BACKGROUND: Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients. METHODS: We analyzed data from a large clinical trial in PSP-Richardson's syndrome (AL-108-231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated "a little worse" and those rated "unchanged" on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living. RESULTS: The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening. CONCLUSIONS: Clinically meaningful change is measurable on the PSPRS over 6 months. © 2016 International Parkinson and Movement Disorder Society.
Type: | Article |
---|---|
Title: | Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale |
Location: | United States |
DOI: | 10.1002/mds.26694 |
Publisher version: | https://doi.org/10.1002/mds.26694 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | Minimal clinically important change (MCIC), progressive supranuclear palsy (PSP), progressive supranuclear palsy rating scale (PSPRS), Aged, Disease Progression, Female, Humans, Male, Middle Aged, Minimal Clinically Important Difference, Oligopeptides, Severity of Illness Index, Supranuclear Palsy, Progressive |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences |
URI: | https://discovery.ucl.ac.uk/id/eprint/10055853 |




Archive Staff Only
![]() |
View Item |